Assalamualaikum Wr. Wb., Alhamdulillah awak lai bisa baranti marokok hanyo dek niat sehat takuik jo kanker alias panyakik dan kantong kariang. Bagi dunsanak yang indak bisa baranti marokok iyo manunggu vaccine ko th. 2010, antah lai hiduik juo awak antah indak, karano iko rahasio Allah SWT. Wass, syb.
Study: Anti-nicotine Vaccine Could Help Smokers Quit Smoking By John Soltes May 15, 2005, 23:10 ORLANDO, Fla., May 14 - An anti-nicotine vaccine candidate CYT002-NicQb made by Cytos Biotechnology AG proved effective in helping smokers quit smoking, according to a study announced on May 14 at the Annual meeting of the American Society of Clinical Oncology in Orlando, Florida. The study, led by Jacques Cornuz of the Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland, was to assess the safety, tolerability and efficacy of the anti-nicotine vaccine candidate in treating nicotine addiction. 341 smokers aged 18 to 70 took part in the study. All participants had been smoking 10 to 40 cigarettes a day for at least three years. In the study, two thirds of the participants received five different doses of the anti-nicotine addiction vaccine over four months, whereas one third received a placebo. Efficacy of the vaccine was assessed between 8 weeks and 24 weeks after the treatment. All of those who received the vaccine had an anti-nicotine antibody response, which corresponds to an immunological response rate of 100%. 33 percent of those who received the vaccine responded well and obtained a high level of antibodies. Among those who responded to the anti-nicotine vaccine with high levels of antibodies, 57 percent quit smoking. Those who responded to the anti-nicotine vaccine with low or medium levels of antibodies did not perform better than those in the placebo group. 31 percent of the smokers on a placebo quit smoking. The smokers that quit remained nicotine-free for six months. The anti-nicotine vaccine was safe and only local injection site reactions and flu-like symptoms, which usually disappeared within 24 hours, were occasionally observed. "I am very excited about the outcome of this study, as the data clearly suggest that antibodies against nicotine are effective in helping people quit smoking," said Dr. Jacques Cornuz. If all goes well with the follow-up studies, Cytos Biotechnology hopes to have the anti-nicotine vaccine on the market by 2010, according to Dr. Wolfgang Renner, Chief Executive Officer of Cytos Biotechnology. The anti-nicotine addiction vaccine is based upon a bacteriophage virus, which is an anti-bacterial virus. There are 1.3 billion smokers worldwide. 87 percent of lung cancer cases are due to smoking, while 30 percent of overall cancer statistics are attributed to tobacco smoking. _____________________________________________________ Berhenti/mengganti konfigurasi keanggotaan anda, silahkan ke: http://rantaunet.org/palanta-setting ------------------------------------------------------------ Tata Tertib Palanta RantauNet: http://rantaunet.org/palanta-tatatertib ____________________________________________________
